SensDx qualified to the third and final stage of the prestigious Innostars contest! At the end of November 8 innovative companies will present not only their technology, but also their business idea in front of experienced consultants.

78 projects from Italian, Portuguese, Greek, Hungarian and Polish startups were submitted to the InnoStars contest, organized by the international consortium, EIT Health. After evaluation of international experts 20 went through to the second stage and 8 to the final, including SensDx.

The project submitted to the contest concerns the development of the technology of ultra-precise tests for fast diagnosis of particular pathogens. They allow to detect many potential diseases in home conditions. The innovation of the solution is based on a combination of a simple to use device and an ultra-sensitive, fast diagnostic test with an mobile application to easily and conveniently read the results of the diagnosis.

It is a huge success for us – says Katarzyna Pala, Ph.D., Head of Business Development in SensDx. – We are among many great Central European companies. The experts appreciated not only our technology, but also the business model we proposed. We are a young, thriving company, so this a big achievement for us.

Distinction of SensDx in a highly valued contest is a great opportunity, that will definitely bring many profits. EIT Health is a powerful network including such big institutions as Roche, Sanofi Aventis, Philips Electronics, Intel Corporation, Max Planck Society, Karolinska Institute, Imperial College in London, Universities in Uppsali, Gent, Cambridge and Oxford and many others. SensDx will have the opportunity to use the reputation and experience of the partners, which is a unique opportunity to develop and have an international research cooperation based on the support of research facilities from all over Europe.

We want to revolutionize telemedicine on the world by delivering precise, fast and easy to use diagnostic tests with the highest sensitivity and at the same the cheapest on the market. This is our ambition and the final of the InnoStars contest is a next step, which will allow us to verify it before authorities of the MedTech sector – dr Pala adds.